Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

about

Positioning novel biologicals in CKD-mineral and bone disorders.Denosumab for Male Hemodialysis Patients with Low Bone Mineral Density: A Case-Control Study

P2860

Q39328170-21717277-1887-46BB-9E02-DE7E649B27A7 Q41622523-95A4D2EA-F701-4C7B-A4DF-8C3B77E166A2

P2860

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

Item

http://www.wikidata.org/entity/Q39618928

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

@en

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

@nl

type

Item

label

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

@en

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

@nl

prefLabel

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

@en

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

@nl

P1476

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

@en

P2093

Alessandra Moioli

http://www.w3.org/2001/XMLSchema#string

Claudia Fofi

http://www.w3.org/2001/XMLSchema#string

Giorgio Punzo

http://www.w3.org/2001/XMLSchema#string

Maryam Tayefeh Jafari

http://www.w3.org/2001/XMLSchema#string

Paolo Menè

http://www.w3.org/2001/XMLSchema#string

Salvatore Sciacchitano

http://www.w3.org/2001/XMLSchema#string

Simona Barberi

http://www.w3.org/2001/XMLSchema#string

Stefano Amendola

http://www.w3.org/2001/XMLSchema#string

P2860

Can one evaluate bone disease in chronic kidney disease without a biopsy?

Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)

Increasing options for the treatment of osteoporosis

Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system

Chronic kidney disease and bone fracture: a growing concern

Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.

Update on denosumab treatment in postmenopausal women with osteoporosis.

Marked increase in bone formation markers after cinacalcet treatment by mechanisms distinct from hungry bone syndrome in a haemodialysis patient.

Activation of beta-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult beta-catenin conditional activation mice.

Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw.

P2888

s40620-016-0334-1

P304

271-279

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40620-016-0334-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francescaromana Festuccia

P577

2016-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27394428

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

about

P2860

P2860

Safety and efficacy of denosumab in osteoporotic hemodialysed patients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921